Home/News Feed/10x Genomics gains with legal win, analyst coverage, and new product launch boosting growth outlook.
10x Genomics received a “Sector Perform” rating and $70 price target from RBC Capital, indicating a 12% potential upside. The company won a $4.8 million patent infringement lawsuit, strengthening its market position. Its upcoming Atera product is expected to increase instrument sales in late 2026 and generate recurring revenue from 2027, supporting future growth. These developments highlight 10x Genomics’ strong innovation and competitive edge in life sciences technology.
